Alterations of gut microbiome in autoimmune hepatitisOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study characterized gut dysbiosis in autoimmune hepatitis (AIH), a liver disease increasingly linked to the liver-microbiome axis. The goal was rigorous profiling before any steroid treatment could confound results. Researchers ran a cross-sectional study using 16S rRNA gene sequencing of fecal samples. They compared people with AIH to matched healthy controls. All patients were sampled before corticosteroid therapy. An independent second cohort was analyzed to validate the microbial findings and test a diagnostic taxa panel.
Who was studied?
Subjects were human adults with autoimmune hepatitis and healthy controls. The main cohort included 91 corticosteroid treatment-naive AIH patients and 98 matched healthy controls. An independent validation cohort added 28 patients and 34 controls. The study spanned a broad adult age range and included both women and men. Sampling patients before any steroid therapy was a deliberate design choice. It let the researchers link microbial features to the disease itself rather than to immunosuppressive treatment.
What were the most important findings?
AIH gut microbiomes showed lower alpha diversity, with reduced Shannon index and fewer observed operational taxonomic units (both P < 0.01). Overall composition differed significantly from controls (P = 0.002). Obligate anaerobes were depleted while potential pathobionts expanded. Veillonella was the most strongly disease-associated taxon (P = 8.85E-8) and correlated positively with serum aspartate aminotransferase and liver inflammation. A combination of four AIH-associated genera distinguished patients from controls with an area under the curve near 0.8 in both cohorts. Predicted lipopolysaccharide biosynthesis and amino acid metabolism modules were altered.
What are the greatest implications of this study?
The study establishes both compositional and functional gut microbiome changes in untreated autoimmune hepatitis. It points to gut microbiota as candidate non-invasive biomarkers of disease activity. Because Veillonella tracked with aspartate aminotransferase and inflammation, it may reflect ongoing liver injury. These are correlations, so causation is not established. Altered lipopolysaccharide biosynthesis and amino acid metabolism suggest bacteria could generate immunomodulatory signals relevant to autoimmunity. Sampling before steroids strengthens the link to disease rather than treatment.